Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

The Quick Take
The epilepsy market is expected to grow due to an increase in disease prevalence and the expected launch of emerging therapies, including Azetukalner (XEN1101; Xenon Pharmaceuticals), ABS-1230 (Actio Biosciences), BHV-7000 (Biohaven Pharmaceuticals), Relutrigine (PRAX-562; Praxis...
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.



